welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy
study id #: NCT03333590
condition: Duchenne Muscular Dystrophy
status: active, not recruitingpurpose:
The proposed clinical trial study of rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy (DMD) patients. There will be a modified intravascular limb infusion (ILI) procedure that will be used to sequentially deliver vector to each whole lower limb of DMD subjects via a major lower limb artery.
mechanism of action: Gene therapy to introduce a version of dystrophin
last updated: February 27, 2020
start date: November 6, 2017
estimated completion: November 2020
phase of development: Phase 1/Phase 2
size / enrollment: 6
This is an open-label, dose escalation trial where the vector will be delivered via the femoral artery to the muscles of both legs of DMD subjects.
The primary objective of this study is the assessment of the safety of intravascular administration of rAAVrh74.MCK.GALGT2 to DMD patients. Safety endpoints will be assessed by changes in hematology, serum chemistry, urinalysis, immunologic response to rAAVrh74 and GALGT2, and reported history and observations of symptoms. Efficacy measures will be used as secondary outcome for this disorder including a combination of functional 6 minute walk test (6MWT) and direct muscle testing for strength (MVICT) of lower limb muscles.
Subjects will be evaluated at baseline, infusion visit (days 0-2), and return for follow up visits on days 7, 14, 30, 60, 90, and 180 and months 12, 18 and 24
- The primary objective is assessment of safety based on the development of unacceptable toxicity. [Time Frame: 2 years]
Unacceptable toxicity is defined as the occurrence of two or more unanticipated Grade III or higher treatment-related toxicities.
- Expression of GALGT2 as demonstrated by immunofluorescent staining with anti-CT epitope antibodies or WFA lectin in muscle biopsy sections at 90 and 180 days post-injection [Time Frame: 90 and 180 Days]
- GALGT2 protein expression quantified by western blot and assessed by densitometry in muscle biopsy tissue at 90 and 180 days post-injection [Time Frame: 90 and 180 Days]
• Ambulant patients age 4 years or older
• Confirmed mutations in the DMD gene using a clinical accepted technique that completely defines the mutation 1,2
• Measurably impaired muscle function (defined as less than 80% of the predicted value for 100 MWT), but with sufficient muscle preservation to ensure assessment of muscle transfection based on clinical evaluation by the PI and expert colleagues. This degree of preservation will include:
-Ability to extend the knee fully against gravity
-Preserved ambulation with ability to walk >= 350 meters during the 6MWT
-A magnetic resonance image of the quadriceps showing preservation of sufficient muscle mass to permit transfection
• Males of any ethnic group will be eligible
• Ability to cooperate with muscle testing
• Stable daily dose of corticosteroid therapy (including either prednisone, prednisolone, deflazacort or their generic forms) for 12 weeks prior to gene transfer
• Active viral infection based on clinical observations
• The presence of a DMD mutation without weakness or loss of function
• Subject is amenable to or is currently being treated with eteplirsen
• Symptoms or signs of cardiomyopathy, including:
- Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
- Echocardiogram with ejection fraction below 40%
• Serological evidence of HIV infection, or Hepatitis B or C infection
• Diagnosis of (or ongoing treatment for) an autoimmune disease
• Persistent leukopenia or leukocytosis (WBC <= 3.5 K/µL or >= 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
• Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
• Subjects with rAAVrh74 binding antibody titers >= 1:50 as determined by ELISA immunoassay
• Presence of circulating anti-Sda antibodies as determined by study approved laboratory
• Abnormal laboratory values in the clinically significant range, based upon normal values in the Nationwide Children's Hospital Laboratory
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With ...The primary objective of Parts 1 and 2 o...
AAV-Based Gene Therapies for the Muscular DystrophiesMuscular dystrophy is a group of progres...
Priorities When Deciding on Participation in Early-Phase Gene Therapy Trials for Duchenne Muscular Dystrophy: A Best...Purpose: Several gene therapy trials fo...
Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)Duchenne/Becker muscular dystrophy (DMD/...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular DystrophyWhile it has been known for many years t...
NCATS, FDA Co-Host Workshop on Gene Therapy for Rare Diseases“We are now at the point of translatin...